Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
The antiresorptive effect of a single 60-mg injection of the RANKL (receptor activator of NFkappaB ligand)-specific mAb, denosumab, substantially exceeds the effects of alendronic acid (70 mg weekly) yet increases in bone mass at the lumbar spine are identical for both agents. Important experimental and clinical observations illustrating some of the potential consequences of osteoclast deficiency and low-rate bone resorption for osteoblast function, bone mineralization, bone quality and related mechanical properties are summarized. This review also discusses whether the benefits for bone health can be improved when aggressively pushing the limits with novel antiresorptive medications.
Tankó
László B
LB
Nordic Biotech Advisors A/S, Østergade 5, 3rd Floor, 1100 Copenhagen K, Denmark. lbt1970@gmail.com
D019386:Alendronate / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D002452:Cell Count; D000069448:Denosumab; D006801:Humans; D010010:Osteoclasts / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000378:metabolism; D053244:Osteoprotegerin / Q000502:physiology; D053245:RANK Ligand / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000378:metabolism / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D000069448:Denosumab; D019386:Alendronate